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Background: To evaluate safety, pharmacokinetics, and maximum tolerated dose of roniciclib in patients with advanced
malignancies, with dose expansion to evaluate clinical benefit at the recommended phase II dose (RP2D).
Methods: Two phase I dose-escalation studies evaluated two roniciclib dosing schedules: 3 days on/4 days off or 4 weeks on/
2 weeks off. The expansion phase included patients with small-cell lung cancer (SCLC), ovarian cancer, or tumour mutations
involving the CDK signalling pathway.
Results: Ten patients were evaluable in the 4 weeks on/2 weeks off schedule (terminated following limited tolerability) and 47 in
the 3 days on/4 days off schedule dose-escalation cohorts. On the 3 days on/4 days off schedule, RP2D was 5 mg twice daily in
solid tumours (n ¼ 40); undetermined in lymphoid malignancies (n ¼ 7). Common roniciclib-related adverse events included
nausea (76.6%), fatigue (65.8%), diarrhoea (63.1%), and vomiting (57.7%). Roniciclib demonstrated rapid absorption and doseproportional increase in exposure. One partial response (1.0%) was observed. In RP2D expansion cohorts, the disease control rate
(DCR) was 40.9% for patients with ovarian cancer (n ¼ 25), 17.4% for patients with SCLC (n ¼ 33), and 33.3% for patients with CDKrelated tumour mutations (n ¼ 6).
Conclusions: Roniciclib demonstrated an acceptable safety profile and moderate DCR in 3 days on/4 days off schedule.
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Cyclin-dependent kinases (CDKs) are key regulators of cell
division and other fundamental cellular functions including gene
transcription (Nurse et al, 1998). Through overexpression or
amplification of cell-cycle activators (e.g., D- or E-type cyclins,
CDK4, CDK6) and by inactivation of cell-cycle inhibitors, CDKs
contribute to deregulation of the cell cycle in tumour cells
(Lapenna and Giordano, 2009; Asghar et al, 2015). CDKs are also
involved in regulating basal transcription: for example, CDK7 and
CDK9 are involved in the phosphorylation of RNA polymerase II,
contributing to initiation and elongation of transcription, respectively (Spangler et al, 2001; Asghar et al, 2015). Polymorphisms of
CDK7 and overexpression of CDK9 have been associated with a
wide variety of cancer tissues (Peyressatre et al, 2015). The vital
role of CDKs in regulating cell proliferation and transcription
suggests that the inhibition of CDKs may be a potential therapeutic
target in cancer. Selective inhibition of CDKs 4 and 6 has proven to
be active in oestrogen receptor-positive breast cancer when used in
combination with letrozole, but is limited to malignancies with an
intact retinoblastoma gene (Witkiewicz and Knudsen, 2014). A
broad-spectrum CDK inhibition profile may be dependent on
factors such as tumour type, CDK expression levels, and
mutational profile.
Roniciclib (BAY 1000394; Bayer AG, Leverkusen, Germany) is
an oral, small-molecule pan-CDK inhibitor with low nanomolar
activity against cell-cycle CDKs 1, 2, 4, and 6 and transcriptional
CDKs 7 and 9. Roniciclib demonstrated favourable preclinical
pharmacokinetic (PK) parameters, with a low clearance and an
intermediate half-life across species following intravenous administration and a high volume of distribution, suggesting extensive
tissue distribution (Siemeister et al, 2012). After oral application,
roniciclib was readily absorbed and showed an intermediate
bioavailability of B50%. Roniciclib was shown to have broadspectrum anti-proliferative activity in a large panel of human
cancer cell lines of various tumours of diverse genetic backgrounds,
and strongly inhibited tumour growth in a dose-dependent manner
in xenograft mouse models, including models refractory to
standard-of-care drugs (Siemeister et al, 2012). Roniciclib also
demonstrated an additive efficacy in combination with cisplatin
and etoposide without worsening tolerability of treatment in smallcell lung cancer (SCLC) xenograft models (Siemeister et al, 2012).
A human starting dose of 0.01 mg kg  1 (0.37 mg m  2) was
recommended based on preclinical data, including target organ
toxicities in the gastrointestinal tract, reproductive organs, and
lymphohaematopoietic system; similar in vivo efficacy responses
upon various dosing schedules were also observed (Siemeister et al,
2012). Pharmacokinetic and pharmacodynamic data indicated that
once-daily dosing of roniciclib achieved a coverage of the cellular
anti-proliferative IC50 for 1 day, suggesting nearly complete target
inhibition for twice-daily (BID) dosing with a time frame sufficient
to cause profound anti-proliferative and cell death-inducing effects
(Siemeister et al, 2012).
Here we report two parallel first-in-human phase I studies that
evaluated the safety, tolerability, PK, and maximum tolerated dose
(MTD) of roniciclib given in a 3 days on/4 days off schedule
(NCT01188252) or a 4 weeks on/2 weeks off schedule
(NCT01335256) in patients with advanced malignancies. An
expansion phase with the recommended phase II dose (RP2D)
then assessed the clinical benefit of roniciclib 3 days on/4 days off
in patients with SCLC or ovarian cancer, or with solid tumours
bearing a distinct tumour mutation in the CDK signalling pathway.

MATERIALS AND METHODS

Both studies were approved by independent ethics committees and
institutional review boards for each study site, and were conducted
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in accordance with the Declaration of Helsinki and Good Clinical
Practice. All patients provided written, informed consent before
participation.
Study designs. These multicentre, open-label, non-randomised,
phase I dose-escalation studies consisted of two dosing schedules:
4 weeks on/2 weeks off (42-day cycle) or 3 days on/4 days off (21day cycle). The primary objective of both studies was to determine
the safety and MTD of roniciclib in patients with advanced
malignancies. The secondary objectives included assessment of PK,
biomarkers, and tumour response profiles.
In the 4 weeks on/2 weeks off schedule, the dose-escalation
phase of the study was planned for B30 patients with advanced,
histologically or cytologically confirmed solid tumours, with up to
25 additional patients planned for an expansion phase at the MTD.
In the 3 days on/4 days off schedule, the study involved nine
dose-escalation cohorts of patients with solid tumours and two
dose-escalation cohorts of patients with tumours of lymphoid
tissues (cohorts L1 and L2). Expansion cohorts at the MTD were
planned in patients with SCLC (25 patients), ovarian cancer
(25 patients), and tumour mutations involving CDK signalling
such as amplification of cyclin D or E or loss of p15 or p16
(six patients). As part of the SCLC cohort, the effect of a highcalorie, high-fat meal on roniciclib PK was investigated.
Treatment. In both studies, increasing doses of roniciclib were
administered, starting with a dose of 0.3 mg in a polyethylene
glycol-based liquid service formulation, then changing to a tablet
formulation at a dose of 5 mg. A bridging cohort compared the
bioavailability of the two formulations (in the 3 days on/4 days off
schedule only). Details of the dose-escalation schedule are provided
in the Supplementary Materials. A dose-limiting toxicity (DLT)
was defined by the occurrence of any of the following attributed to
roniciclib during cycle 1 of a dose level: absolute neutrophil count
o0.5  109 l  1 for X7 days; febrile neutropenia with absolute
neutrophil count o0.5  109 l  1 and fever X38.5 1C; platelets
o25  109 l  1; any grade 3–5 non-haematological toxicity without
a clear alternative explanation; or any grade 4 vomiting.
Roniciclib was administered BID either on a 4 weeks on/2 weeks
off schedule of a 42-day cycle or on a 3 days on/4 days off schedule
of a 21-day cycle. For PK assessment, a single dose of roniciclib was
given on cycle 1, day 1 in both studies and then BID dosing on
day 3 for the 4 weeks on/2 weeks off schedule and day 2 for the
3 days on/4 days off schedule. The formulation bridging and
food-effect cohorts (3 days on/4 days off schedule only) also had a
single dose on cycle 1, day  3. The effect of a high-fat meal on the
PK of roniciclib was assessed at the RP2D after administration of
roniciclib tablets immediately following consumption of a high-fat,
high-calorie meal on cycle 1, day  3.
Dose escalation would not continue in either study if a DLT
occurred in more than one of six patients, or in two patients within
one cohort. The dose one level below the toxic dose determined the
MTD. Patients continued roniciclib therapy until tumour progression, unacceptable toxicity, consent withdrawal, or withdrawal
from the study at the discretion of the investigator.
Inclusion criteria. Patients were eligible if they were aged 18 years
or older and had histologically or cytologically confirmed solid
tumours, or tumours of lymphoid tissue refractory to or not
amenable to standard therapy. Patients with solid tumours had to
have at least one measurable or evaluable tumour lesion according
to Response Evaluation Criteria in Solid Tumors version 1.1.
Patients with solid tumours bearing a distinct tumour mutation in
the CDK signalling pathway, such as amplification of cyclin D or E
or loss of p15 or p16, were enrolled in an additional cohort.
Patients had to have a life expectancy of 12 weeks or more and an
Eastern Cooperative Oncology Group performance status of 0 or 1.
Progressive disease at baseline was not a requirement for study
www.bjcancer.com | DOI:10.1038/bjc.2017.92
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participation. Further inclusion and exclusion criteria are provided
in the Supplementary Materials.
Assessments. Safety evaluations included adverse events (AEs),
vital signs, laboratory tests, and 12-lead electrocardiograms at
screening, at planned times during each cycle, during follow-up,
and up to 30 days after the last dose. Adverse events were graded
using the National Cancer Institute Common Terminology Criteria
for Adverse Events version 4.0. All patients receiving at least one
dose of roniciclib were included in the safety analysis set.
Pharmacokinetic assessments of single-dose and multiple-dose
roniciclib were planned in the 4 weeks on/2 weeks off schedule and
the 3 days on/4 days off schedule in all patients in the doseescalation phase, and in at least six patients in each tumour type in
the expansion cohorts. The schedule for plasma collection is
provided in the Supplementary Materials. Pharmacokinetic data
were analysed using non-compartmental methods to estimate
maximum drug concentration (Cmax), time to maximum drug
concentration (tmax), area under the curve (AUC), AUC from 0 to
12 h after administration (AUC(0–12)), AUC from 0 to 24 h after
administration (AUC(0–24)), and half-life of roniciclib and its
metabolite, M-1, if possible.
Pharmacodynamic biomarker assessment was performed in the
3 days on/4 days off schedule in the expansion cohorts. The level of
expression of proliferating cell nuclear antigen (PCNA) changes
during the cell cycle and is associated with cell proliferation or
transformation (Stoimenov and Helleday, 2009). Whole blood was
collected in PAXgene Blood RNA Tubes (PreAnalytiX GmbH,
Hombrechtikon, Switzerland). The schedule for sample collection
is provided in the Supplementary Materials. RNA was isolated
following the manufacturer’s instructions. Proliferating cell nuclear
antigen expression as determined by TaqMan real-time polymerase
chain reaction (TaqMan PCNA gene expression assay
Hs00427214_g1; Thermo Fisher Scientific Inc., Waltham, MA,
USA) was normalised to control genes (GAPDH Hs9999905_m1,
SELL Hs01046459_m1, and IGSF6 Hs00175526-m1). All gene
expression assays were purchased from Life Technologies (Carlsbad, CA, USA). Proliferating cell nuclear antigen data were preprocessed using the 2  DDCT method (Livak and Schmittgen, 2001).
Further details of sample collection in the formulation bridging
and food-effect cohorts and for analysis of circulating tumour cells
are provided in the Supplementary Materials.
Investigators assessed response using Response Evaluation
Criteria in Solid Tumors version 1.1 in patients with solid
tumours, and using the pertinent guidelines in patients with
tumours of lymphoid tissue. Stable disease was defined as neither
sufficient shrinkage to qualify for partial response nor sufficient
increase to qualify for progressive disease, taking as reference the
smallest sum diameters at first assessment (after cycle 2).
Assessments were made every two cycles in the 3 days on/4 days
off schedule and at the end of each cycle for the 4 weeks on/2 weeks
off schedule. Response was evaluated in all patients who received
study treatment, including patients with missing evaluations or
who were not assessed.
Statistical analyses. Descriptive statistics were used to summarise
demographic data and other baseline characteristics, AEs, safety
parameters, and tumour assessment data. The relative bioavailability of the liquid and tablet formulations and the food effect on
single-dose roniciclib were compared based on roniciclib PK
parameters, primarily on AUC(0–24) and Cmax, on cycle 1, day  3
and cycle 1, day 1.
RESULTS

Baseline patient demographics and disease characteristics.
Fifteen patients with solid malignant tumours who progressed
www.bjcancer.com | DOI:10.1038/bjc.2017.92
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after standard therapy were enrolled in the 4 weeks on/2 weeks off
schedule, 10 of whom received treatment and were evaluable for
safety and tumour response. The median age at screening was
50.5 years (range, 42–76), and 40% of patients were female. Cancer
diagnosis is reported in Supplementary Table 1. Prior systemic
therapies were reported in 100% of patients (Table 1). Four
patients were assigned to the first dosing cohort (0.3 mg BID) and
six patients to the second dosing cohort (0.5 mg BID).
A total of 148 patients were enrolled in the 3 days on/4 days off
schedule, with 111 receiving treatment and evaluable for safety and
tumour response. Overall, 40 patients were enrolled in the solidtumour dose-escalation cohorts.
In the 3 days on/4 days off schedule, 55.0% of patients were
female and median age was 59 years (range, 26–80; Table 1).
Approximately half of patients (50.5%; 56 patients) had more than
three prior systemic anti-cancer therapies (range, 1–11). Patients
with SCLC received 1–5 prior lines of treatment (median of two),
and patients with ovarian cancer received 3–11 prior lines of
treatment (median of five). Colon cancer (nine patients) and
mesothelioma (five patients) were the most frequently reported
cancer diagnoses in the solid-tumour dose-escalation cohorts (see
Supplementary Table 1 for cancer diagnoses).
Dose escalation and RP2D. One patient experienced a DLT in the
0.5 mg BID cohort (hyponatraemia), and several other patients
experienced various treatment-emergent AEs (TEAEs) affecting
the dose-escalation scheme. Therefore, the study with roniciclib
administered in the 4 weeks on/2 weeks off schedule was
terminated due to limited tolerability (see additional details below).
Enrolment and dose escalation in the 3 days on/4 days off
schedule using the polyethylene glycol-based liquid service formulation proceeded according to protocol until cohort 6 (9.6 mg BID,
formulation bridging cohort), where one patient experienced a DLT
(hyponatraemia) leading to expansion of the cohort to six patients.
Subsequent dose levels used the 5 mg tablet formulation at 5 mg BID
(cohort 7, n ¼ 4), 5/10 mg BID (cohort 8, n ¼ 7; 5 mg in the
morning, 10 mg in the evening), and 10 mg BID (cohort 9, n ¼ 7).
The 5/10 mg BID dose was initially defined as the MTD for the
expansion cohorts. However, after the enrolment of two patients
with SCLC and three with ovarian cancer at this dose, the RP2D was
changed to 5 mg BID based on safety observations (see below). An
additional 59 patients with solid tumours were enrolled in the doseexpansion cohorts with the RP2D (SCLC, n ¼ 31; ovarian cancer,
n ¼ 22; and CDK-related tumour mutation, n ¼ 6).
Seven patients were enrolled in the lymphoid malignancy doseescalation cohorts, 5 mg once daily (n ¼ 3) and 5 mg BID (n ¼ 4)
(see Supplementary Table 1 for cancer diagnoses). Recruitment was
stopped before the third dose level because the recruitment rate did
not suggest a proper completion of the study within a reasonable
time frame.
Exposure and safety. Continuous BID dosing in the 4 weeks
on/2 weeks off schedule was not well tolerated. The mean
treatment duration was 5.5 weeks (range, 4–10) in the 0.3 mg
BID cohort and 7.2 weeks (range, 1–22) in the 0.5 mg BID cohort,
with most patients on the study treatment for 4 or more weeks
(three out of four patients in the 0.3 mg BID cohort; four out of six
patients in the 0.5 mg BID cohort). One patient in the 0.5 mg BID
cohort experienced a DLT of grade 3 hyponatraemia, which
resolved 3 days after treatment interruption.
The most commonly reported TEAEs were nausea, fatigue, fever,
dyspepsia, constipation, vomiting, pain, increased aspartate aminotransferase, and hot flashes (Supplementary Table 2). No grade 4 or 5
TEAEs were reported. One patient permanently discontinued
roniciclib because of treatment-emergent lower-extremity oedema
(grade 3). Due to the DLT and other drug-related TEAEs affecting
the dose-escalation scheme, it was apparent that the study would not
be completed within the specified time frame. Therefore, the sponsor
1507
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Table 1. Baseline patient demographics and disease characteristics
4 weeks on/
2 weeks off schedule
Dose-escalation
cohorts

Median age,
years (range)
Females, n (%)

3 days on/4 days off schedule

Dose-escalation cohorts

Dose-expansion cohorts

Lymphoid
SCLC 5 mg BID
tissue tumour or 5/10 mg BID
(n ¼ 7)
(n ¼ 33)

Total

Ovarian cancer
5 mg BID or
5/10 mg BID
(n ¼ 25)

Tumour
mutation 5 mg
BID
(n ¼ 6)

(N ¼ 111)

Solid tumour
(n ¼ 10)

Solid tumour
(n ¼ 40)

50.5 (42–76)

58.0 (26–73)

63.0 (36–76)

60.7 (46–80)

59.0 (28–75)

54.5 (43–65)

59.0 (26–80)

4 (40.0)

16 (40.0)

1 (14.3)

15 (45.5)

25 (100)

4 (66.7)

61 (55.0)

1 (10.0)
8 (80.0)
–

24 (60.0)
12 (30.0)
–

3 (42.9)
3 (42.9)
1 (14.3)

9 (27.3)
23 (69.7)
–

9 (36.0)
14 (56.0)
–

2 (33.3)
4 (66.7)
–

47 (42.3)
56 (50.5)
1 (0.9)

10 (100)

40 (100)

7 (100)

33 (100)

25 (100)

6 (100)

111 (100)

ECOG
performance
statusa, n (%)
0
1
2
Prior systemic
therapy
(neoadjuvant,
adjuvant,
palliative, and/or
curative), n (%)
Prior
radiotherapy,
n (%)

6 (60.0)b

18 (45.0)

3 (42.9)

26 (78.8)

2 (8.0)

4 (66.7)

53 (47.7)

Prior local
therapy, n (%)

1 (10.0)c

1 (2.5)

1 (14.3)

–

2 (8.0)

1 (16.7)

5 (4.5)

Abbreviations: BID ¼ twice daily; ECOG ¼ Eastern Cooperative Oncology Group; SCLC ¼ small-cell lung cancer.
a
Data are missing for seven patients in the 3 days on/4 days off study and one patient in the 4 weeks on/2 weeks off study.
b
Data are missing for four patients.
c
Data are missing for nine patients.

Liquid formulations

Tablet formulations

0.3 mg BID 0.6 mg BID 1.2 mg BID 2.4 mg BID 4.8 mg BID 9.6 mg BID
(n=3)
(n=4)
(n=3)
(n=3)
(n=3)
(n=6)

5 mg BID 5/10 mg BID 10 mg BID
(n=4)
(n=7)
(n=7)

2 DLTs

1 DLT

2 DLTs

Figure 1. Patient disposition during dose escalation on the 3 days on/4 days off schedule.

chose to terminate the study after the enrolment of the first
10 patients. Ongoing patients were allowed to continue treatment.
An MTD was not determined for continuous BID dosing in a
4 weeks on/2 weeks off schedule.
In the 3 days on/4 days off schedule in solid tumours, patients
received a median of two cycles (range, 1–12), and median
treatment duration was 41 days (range, 1–252), with the majority
of patients (73.9%) continuing treatment for less than 50 days.
Dose-limiting toxicities occurred in five patients in the solidtumour dose-escalation cohorts (Figure 1). Two out of six patients
in the 9.6 mg BID cohort, using the polyethylene glycol-based
liquid service formulation, reported DLTs (hyponatraemia and oral
mucositis), of which mucositis was considered to be related to the
polyethylene glycol content of the liquid service formulation. The
next cohort started with a decreased dose of 5 mg BID using the
tablet formulation, and no DLTs were reported. At 5/10 mg BID,
there was one reported DLT (peripheral ischaemia caused by
arterial thrombosis in a patient with adrenocortical carcinoma with
involvement of the aorta). In the 10 mg BID cohort, two out of six
patients reported DLTs (anorexia and elevated troponin). Elevated
troponin was considered a thromboembolic event and occurred in
a patient with thyroid cancer and a history of aneurysm of the
abdominal aorta, cardiac infarction, and ischaemic heart disease.
1508

The MTD was determined to be 5/10 mg BID. After the occurrence
of three additional thromboembolic events during the 5/10 mg
expansion phase (arterial embolism in a patient with ovarian
cancer, pulmonary embolism in a patient with SCLC, and
intracardial thrombosis in a patient with ovarian cancer), the
MTD was reassessed and considered to be 5 mg BID. In the 5 mg
BID expansion cohorts, the thromboembolic event rate was 7.9%.
No DLT was reported in the lymphoid malignancy doseescalation cohorts at doses up to 5 mg BID.
At least one dose modification (reduction or interruption) was
reported in 70 patients (63.1%) across all cohorts: 23 patients
(20.7%) had dose reductions and 66 patients (59.5%) had dose
interruptions or delays, with 44 patients having a single episode.
Roniciclib treatment was permanently discontinued in the majority
of patients because of disease progression (69 patients; 62.2%),
while an additional 12 patients (10.8%) experienced an AE
associated with clinical disease progression and discontinued
permanently.
The most commonly reported TEAEs of any grade across all
cohorts of patients in the 3 days on/4 days off schedule included
nausea (80.2%), fatigue (72.1%), diarrhoea (64.9%), and vomiting
(61.3%; Supplementary Table 3). Nausea was managed by
concomitant anti-emetic medications.
www.bjcancer.com | DOI:10.1038/bjc.2017.92
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Overall, 66 patients (59.5%) experienced an AE of grade 3
(42.3%), 4 (5.4%), or 5 (11.7%). Roniciclib-related TEAEs of any
grade were reported in 106 patients (95.5%), with nausea (76.6%),
fatigue (65.8%), diarrhoea (63.1%), and vomiting (57.7%) occurring most frequently (Supplementary Table 4). The most common
grade 3 roniciclib-related TEAEs were fatigue (7.2%), nausea
(5.4%), hypotension (3.6%), and anorexia (3.6%); only two
roniciclib-related grade 4 TEAEs were reported (thromboembolic
event and peripheral ischaemia; Table 2). Relevant treatmentemergent changes in coagulation parameters, including factor VIII,
D-dimers, and von Willebrand factor antigen, were not observed.
Serious TEAEs were reported in 46 patients (41.4%), with the
most common being venous and arterial thromboembolic events
(eight patients (7.2%), including a case of peripheral ischaemia
caused by an arterial thrombosis), dyspnoea (five patients (4.5%)),
other general disorders (five patients (4.5%); hemiparesis, device
breakage, duodenal obstruction, intestinal obstruction, and general
deterioration), ileus (three patients (2.7%)), and unspecified death
(three patients (2.7%)). Eleven patients had roniciclib-related
serious AEs, with thromboembolic events and peripheral ischaemia
being the most frequent (five patients (4.5%)). Eleven patients died
between the first day of treatment and 30 days post treatment,
primarily because of progressive disease or AEs associated with
progressive disease. Reported grade 5 events included death not
specified (three patients (2.7%)), other general disorders (two
patients (1.8%)), dyspnoea (two patients (1.8%)), and catheterrelated infection, encephalopathy, pleural effusion, and other
infection in one patient each (0.9%). None of these deaths was
attributed to the study drug.
Abnormal electrocardiogram patterns were uncommon across
both studies.
Pharmacokinetic evaluation. In the 3 days on/4 days off schedule,
39 patients were evaluable for PK analysis in the dose-escalation
cohorts, and 31 patients were evaluable in the 5 mg BID doseexpansion cohorts. After oral administration, roniciclib was rapidly
absorbed with both the solution and tablet formulations, with a
median tmax of B1 h (Figure 1). Single-dose roniciclib plasma
concentration–time profiles were similar for both dose-escalation
cohorts (Figure 2) and dose-expansion cohorts (Figure 3).
Geometric mean roniciclib PK parameters are presented in
Supplementary Table 5. Single-dose and multiple-dose geometric
mean PK data indicate that roniciclib exhibits a generally doseproportional increase in exposure in the dose range studied

(0.3–10 mg) with low to moderate inter-patient variability. At the
RP2D (5 mg BID), geometric mean multiple-dose roniciclib Cmax
and AUC(0–12) values of 98.6 mg l  1 and 662 mg  h l  1, respectively, were estimated on cycle 1, day 10 in the expansion cohorts.
On average, roniciclib half-life was estimated to be 8.5 h in the
expansion cohorts, which resulted in an approximately two-fold
accumulation after BID dosing.
After administration of roniciclib 10 mg as tablets and 9.6 mg as
solution formulation, geometric mean roniciclib AUC (from time 0
to the last data point) values were 815 mg  h l  1 and 575 mg 
h l  1, respectively, supporting the transition from solution to
tablet formulation. After the administration of 5 mg roniciclib
tablets immediately following a high-fat, high-calorie meal and
under fasting conditions for seven patients, geometric mean
roniciclib AUC(0–24) values were 318 mg  h l  1 and 511 mg 
h l  1, respectively, indicating a 38% decrease in exposure with
food. After administration under fed and fasting conditions,
geometric mean roniciclib Cmax values were 29.7 mg l  1 and
71.5 mg l  1, respectively, with a delay in reaching maximum
plasma concentrations under fed conditions.
Roniciclib PK parameters were generally comparable in patients
enrolled in the 3 days on/4 days off and 4 weeks on/2 weeks off
schedules. In both studies, exposure to metabolite M-1 was less
than 10% of exposure to roniciclib (data not shown).
Biomarkers. This exploratory analysis aimed to demonstrate the
biological activity of roniciclib and to support the RP2D finding.
The change in mRNA levels of PCNA in whole blood as a
surrogate tissue was determined in response to roniciclib
treatment. Roniciclib significantly inhibited expression of PCNA
(fold-change from baseline) in peripheral whole blood 6 h post
dose on cycle 1, day 1 in ovarian cancer and SCLC patients
(Figure 4).
PCNA RNA expression levels were evaluated in the whole blood
of 59 patients during the expansion phase of the study. The realtime polymerase chain reaction data taken 6 h post dose on cycle 1,
day 1 and cycle 1, day 10 were normalised to the pre-treatment
expression levels of the respective patient. In the expansion
cohorts, 27 patients with ovarian cancer and 32 with SCLC were
analysed. For both indications, a decrease in PCNA RNA levels was
detected on cycle 1, day 1 that was significantly different from the
baseline values (ovarian cancer cohort, DDCT ¼ 1.720, Po0.0001;
SCLC cohort, DDCT ¼ 1.006, Po0.0001). The inhibition of
expression was less pronounced on day 10 and did not reach

Table 2. Summary of treatment-related grade 3 or 4 adverse events occurring in X3 patients (grade 3) or X1 patients (grade 4)
overall in the 3 days on/4 days off schedule
Cohort

Cohort

Cohort

Cohort

Cohort

Cohort 6

Cohort

Cohort

Cohort

Cohort

Cohort

SCLC

SCLC

Ovarian

Ovarian

Tumour

1

2

3

4

5

9.6 mg

7

8

9

L1

L2

cohort

cohort

cohort

cohort

mutation

SCLC foodeffect

0.3 mg

0.6 mg

1.2 mg

2.4 mg

4.8 mg

BID

5 mg

5/10 mg

10 mg

5 mg

5 mg

5/10 mg

5 mg

5/10 mg

5 mg

cohort

cohort

BID

BID

BID

BID

BID

bridging

BID

BID

BID

QD

BID

BID

BID

BID

BID

5 mg BID

5 mg BID

Total

Grade

(n ¼ 3)

(n ¼ 4)

(n ¼ 3)

(n ¼ 3)

(n ¼ 3)

(n ¼ 6)

(n ¼ 4)

(n ¼ 7)

(n ¼ 7)

(n ¼ 3)

(n ¼ 4)

(n ¼ 2)

(n ¼ 23)

(n ¼ 3)

(n ¼ 22)

(n ¼ 6)

(n ¼ 8)

(N ¼ 111)

Fatigue

3

–

–

–

–

–

1 (16.7)

1 (25.0)

–

–

–

–

–

1 (4.3)

–

3 (13.6)

2 (33.3)

–

8 (7.2)

Nausea

3

–

–

–

–

–

1 (16.7)

–

–

–

–

–

2 (8.7)

–

1 (4.5)

1 (16.7)

1 (12.5)

6 (5.4)

Hypotension

3

–

–

–

–

–

–

–

–

1 (14.3)

–

–

–

2 (8.7)

–

1 (4.5)

–

–

4 (3.6)

Anorexia

3

–

–

–

1 (33.3)

–

–

–

–

1 (14.3)

–

–

–

–

–

–

1 (16.7)

1 (12.5)

4 (3.6)

Hyponatraemia

3

–

–

–

–

–

1 (16.7)

–

–

–

–

–

–

1 (4.3)

–

–

–

1 (12.5)

3 (2.7)

Hypophosphatemia

3

–

–

–

–

–

–

–

–

–

–

1 (25.0)

–

1 (4.3)

–

1 (4.5)

–

–

3 (2.7)

Vomiting

3

–

–

–

–

–

–

–

–

–

–

–

–

–

–

2 (9.1)

–

1 (12.5)

3 (2.7)

Thromboembolic
event

3

–

–

–

–

–

–

–

–

–

–

–

–

1 (4.3)

2 (66.7)

–

–

–

3 (2.7)

Thromboembolic
event

4

–

–

–

–

–

–

–

–

–

–

–

1 (50.0)

–

–

–

–

–

1 (0.9)

Peripheral ischaemia

4

–

–

–

–

–

–

–

1 (14.3)

–

–

–

–

–

–

–

–

–

1 (0.9)

Adverse event,
n (%)

–

Abbreviations: BID ¼ twice daily; QD ¼ once daily; SCLC ¼ small-cell lung cancer.
All adverse events were defined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
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Figure 2. Geometric mean single-dose plasma roniciclib
concentration–time profiles on day 1. Dose escalation cohorts 1–6 are
shown in (A) and dose escalation cohorts 7–9 are shown in (B).

significance (ovarian cancer cohort, DDCT ¼ 0.521, P ¼ 0.1618;
SCLC cohort, DDCT ¼ 0.224, P ¼ 0.9663; Supplementary Table 6).
Not enough patients were evaluated in the other cohorts to
make an assessment.
Although roniciclib treatment caused a pharmacodynamic effect
on cycle 1, day 1, no difference between fold-change in PCNA mRNA
levels and best response (stable disease or progressive disease) was
observed in the 31 samples evaluated from 15 patients with ovarian
cancer and 16 patients with SCLC (data not shown). Progressive
disease biomarker data from the patient who achieved a partial
response in the 3 days on/4 days off schedule were not available;
therefore, it was not possible to determine whether a pharmacodynamic effect was observed in blood samples from clinical responders.
Tumour response. No patients in the 4 weeks on/2 weeks off
schedule achieved a complete or partial response; stable disease was
achieved in five patients, giving a disease control rate (DCR) of
50% (95% CI, 18.71–81.29%). Duration of disease control in the
five patients with stable disease ranged from 38 to 153 days. The
patient experiencing stable disease for 153 days had otherwise
refractory melanoma.
Of the 104 patients in the 3 days on/4 days off schedule with
solid tumours, none achieved a complete response, one (1.0%)
achieved a partial response, and 33 (31.7%) achieved stable disease,
giving a response rate of 1.0% (95% CI, 0.0–5.2%) and a DCR of
32.7% (95% CI, 23.8–42.6%) according to Response Evaluation
Criteria in Solid Tumors. Forty patients (38.5%) had radiological
progressive disease and 26 (25.0%) were not assessed due to clinical
progression or termination due to AEs. The patient with the partial
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Figure 3. Individual and geometric mean single-dose plasma roniciclib
concentration–time profiles on day 1. SCLC expansion cohort is shown
in (A) and ovarian cancer expansion cohort (5 mg BID and 5/10 mg BID)
is shown in (B).

response had ovarian cancer and was treated in cohort 8 (5/10 mg
BID). In the 5 mg BID dose-expansion cohorts, the DCR was
higher for patients with ovarian cancer (40.9%; 95% CI,
20.7–63.7%; n ¼ 22) than for patients with SCLC (17.4%; 95%
CI, 5.0–38.8%; n ¼ 23). The DCR for patients with solid tumours
bearing a CDK-related tumour mutation involving CDK signalling
was 33.3% (95% CI, 4.3–77.7%; n ¼ 6).
Of the seven patients in the lymphoid malignancy doseescalation cohorts, none achieved a complete or partial response
and three achieved stable disease, giving a DCR of 42.9% (95% CI,
9.9–81.6%); one patient was not assessed.

DISCUSSION

The aim of the two phase I studies was to assess the safety and
tolerability of the pan-CDK inhibitor roniciclib in patients with
advanced malignancies. Two different schedules were investigated
to determine the optimal dosing strategy.
In contrast to selective CDK4 and 6 inhibitors, pan-CDK
inhibitors do not depend on the presence of an intact
retinoblastoma gene to have anti-tumour activity (Siemeister
et al, 2012). This also allows for their use in indications with
frequent loss-of-function mutations. Pan-CDK inhibitors have
been studied intensively over the past decade, and although there is
a strong mechanistic rationale and promising preclinical data,
compounds in development have not yet met expectations in
clinical trials. Dinaciclib, an inhibitor of CDKs 1, 2, 5, and 9, has
shown encouraging clinical activity as monotherapy and in
www.bjcancer.com | DOI:10.1038/bjc.2017.92
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Visit
Cycle 1, day 1
Cycle 1, day 10

Fold-change in PCNA levels (2–ΔΔCT)

1.5

1.0

*
*

0.5

0.0
Ovarian
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Tumour
mutation

L1
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Figure 4. Changes of PCNA expression levels in whole blood after
roniciclib treatment. The boxplot shows the fold-change of PCNA RNA
expression on day 1 (circle) and day 10 (triangle) of cycle 1 compared
with baseline values for each cohort. Significant changes to baseline
values are depicted by asterisks. Cycle 1, day 1 values for both the
ovarian cancer and SCLC cohorts are significantly different from
baseline PCNA expression. The thick black line in the box indicates the
median value, the upper hinge indicates the 75% quantile, and the
lower hinge indicates the 25% quantile. Upper and lower whiskers
describe the largest or smallest observed values within 1.5-fold of the
interquantile range.

combinations in phase I trials in advanced malignancies and
leukaemia (Nemunaitis et al, 2013; Fabre et al, 2014); however,
phase II studies in non-SCLC and advanced breast cancer were
disappointing (Mita et al, 2014; Stephenson et al, 2014).
One reason for the failure of pan-CDK inhibitors is their harmful
effect on cell-cycle progression of healthy tissues, mainly cells in the
bone marrow and the gastrointestinal linings (Pevarello et al, 2010).
Since pan-CDK inhibitors act on many phases of the cell cycle,
sufficient exposure in the tumour tissue must be reached over its
entire duration. It is therefore critical to identify the optimal dose
and schedule to allow recovery of healthy tissue while delivering
strong anti-proliferative activity. Roniciclib, due to its high solubility
and good bioavailability in mice (Siemeister et al, 2012), was
predicted to provide adequate exposure in the clinical setting.
In line with preclinical data demonstrating that prolonged
exposure of roniciclib was needed to achieve strong antiproliferative activity (Siemeister et al, 2012) and the predicted
intermediate half-life, BID dosing was chosen for clinical trials.
The dosing schedule was not expected to impact on efficacy;
however, a potential impact on the safety and tolerability was
anticipated. Early toxicity after 7 days of treatment and subsequent
patient dropout on the 4 weeks on/2 weeks off schedule suggested
that continuous dosing for 4 weeks was not sustainable, so this
schedule was terminated. In contrast, the intermittent dosing of
roniciclib in the 3 days on/4 days off schedule allowed dose
escalation and therefore a higher exposure, resulting in the MTD of
5/10 mg BID. The intermittent dosing schedule is also supported
by efficacy data generated in animal studies, as dose-dependent
efficacy was observed upon various dosing schedules ranging from
www.bjcancer.com | DOI:10.1038/bjc.2017.92

once daily to cyclic intermittent dosing (Siemeister et al, 2012). As
three additional cases of thromboembolic events (including one
arterial event) occurred in the 5/10 mg BID dose-expansion
cohorts, 5 mg BID was defined as the RP2D. In the 5 mg BID
cohorts, the thromboembolic event rate was 7.9%, which is in the
expected range in this patient population and time frame (Mandala
et al, 2012; Khorana et al, 2013).
Overall, nausea, fatigue, diarrhoea, and vomiting were the most
frequently reported roniciclib-related TEAEs of any grade, and
patients received anti-emetic therapy as needed. The most
frequently reported grade 3 roniciclib-related TEAEs were fatigue,
nausea, anorexia, and hypotension, while only two drug-related
grade 4 TEAEs were reported. In general, TEAEs were as
anticipated given the mechanism of action of roniciclib and
heavily pretreated patients. TEAEs, specifically gastrointestinal
effects, were similar to what has been reported in clinical trials of
other CDK inhibitors (Cicenas et al, 2014; Aleem and Arceci, 2015)
and are likely to be related to the effects on rapidly cycling cells of
the gastrointestinal lining (Kumar et al, 2015). Notably, no marked
effect on neutrophils was observed. This may be because of the
intermittent dosing schedule, allowing sufficient time for recovery,
or because of an exposure below the threshold for cell-cycle
inhibition in progenitor cells or induction of apoptosis in
circulating neutrophils. Overall, with intermittent dosing, the
safety profile was acceptable for use in cancer patients.
In the lymphoid malignancy cohort, the MTD was not
specifically determined. No DLTs were reported in the two doseescalation cohorts, and recruitment was stopped early because of a
poor recruitment rate.
Roniciclib exhibited favourable PK properties with rapid and
reliable absorption, dose-proportional increase in exposure in the
dose range studied, and a half-life that supports BID administration. Detailed analysis of PK data derived in different species and
in humans indicates that exposure with monotherapy in patients is
B50% below simulated efficacious exposure in mice using
monotherapy (unpublished data). However, that same exposure
is in the range of efficacious exposure in mice treated with
roniciclib in combination with chemotherapy (unpublished data).
Because of lower exposure after consumption of a high-fat meal,
roniciclib should be dosed 1 h before, or 2 h after, a meal.
In the 3 days on/4 days off schedule, the solid-tumour cohorts
achieved a DCR of 32.7%. The ovarian cancer and SCLC expansion
cohorts had DCRs of 40.9% and 17.4%, respectively. In the CDKrelated tumour mutation cohort, there was a DCR of 33.3%. In the
lymphoid malignancy cohorts, there was a DCR of 42.9%.
Although no complete or partial responses were achieved in the
expansion cohorts, these DCRs suggest that a potential benefit with
roniciclib treatment cannot be excluded in this heavily pretreated
patient population. Similar DCRs have been seen in phase I trials
of other CDK inhibitors. In phase I trials in advanced
malignancies, the CDK1, 2, 5, and 9 inhibitor dinaciclib
demonstrated a DCR of 20.8% (Nemunaitis et al, 2013) and the
CDK4 and 6 inhibitor palbociclib demonstrated a DCR of 27%
(Flaherty et al, 2012). A phase II study of dinaciclib in previously
treated patients with SCLC demonstrated no objective responses
following treatment (Stephenson et al, 2014).
Proliferating cell nuclear antigen is expressed and can be
determined in peripheral blood cells. Inhibition of PCNA has been
proposed as a pharmacodynamic marker of cell proliferation. In
this study, roniciclib significantly inhibited expression of PCNA in
peripheral whole blood 6 h post dose on cycle 1, day 1 in patients
with ovarian cancer and SCLC. This indicates biologically relevant
exposure of roniciclib at the RP2D. Inhibition of PCNA expression
was less pronounced on day 10.
In summary, data from two phase I trials of roniciclib, a panCDK inhibitor, demonstrate an acceptable safety profile and a
moderate DCR in monotherapy using a 3 days on/4 days off
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schedule in doses up to 5 mg BID in patients with solid malignant
tumours. Inhibition of PCNA was observed in peripheral blood
cells, although the observed exposure is slightly lower than
predicted efficacious exposure. Roniciclib combined with chemotherapy is being explored as first-line therapy in patients with
advanced SCLC (NCT01573338 and NCT02161419).
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